These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8212320)

  • 21. [Effect of nonsteroidal anti-inflammatory agents on the cardiovascular system].
    Stepaniuk GI; Stoliarchuk AA
    Farmakol Toksikol; 1987; 50(5):89-93. PubMed ID: 3319688
    [No Abstract]   [Full Text] [Related]  

  • 22. Connexin 43, a new therapeutic target for cardiovascular diseases.
    Song YN; Zhang H; Zhao JY; Guo XL
    Pharmazie; 2009 May; 64(5):291-5. PubMed ID: 19530438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sex differences and cardiovascular drugs].
    Løchen ML; Kvan E
    Tidsskr Nor Laegeforen; 2010 Feb; 130(4):382-4. PubMed ID: 20220863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leptin and the cardiovascular system - a target for therapeutic interventions.
    Beltowski J
    Curr Pharm Des; 2014; 20(4):601-2. PubMed ID: 23688018
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?
    Roden DM
    Can J Cardiol; 2013 Jan; 29(1):58-66. PubMed ID: 23200096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 7th International Symposium on Cardiovascular Pharmacotherapy. Jerusalem, Israel, June 1-5, 1997. Abstracts.
    Cardiovasc Drugs Ther; 1997 Jun; 11 Suppl 2():315-421. PubMed ID: 9255319
    [No Abstract]   [Full Text] [Related]  

  • 27. Abstracts of the 10th International Congress on Cardiovascular Pharmacotherapy. Kyoto, Japan, 27-31 March 2001.
    Cardiovasc Drugs Ther; 2001 Mar; 15 Suppl 1():1-166. PubMed ID: 11501560
    [No Abstract]   [Full Text] [Related]  

  • 28. More in vivo experimentation is needed in cardiovascular physiology.
    Wier WG
    Am J Physiol Heart Circ Physiol; 2014 Jul; 307(2):H121-3. PubMed ID: 24858850
    [No Abstract]   [Full Text] [Related]  

  • 29. Achieving current goals in prevention and treatment of vascular disease: an update.
    Catapano AL; Elisaf MS; Florentin M; Mikhailidis DP; Kostapanos MS
    Curr Pharm Des; 2013; 19(21):3749-52. PubMed ID: 23286439
    [No Abstract]   [Full Text] [Related]  

  • 30. Emerging role of NET inhibitors in cardiovascular diseases.
    Jayaseelan VP; Paramasivam A
    Hypertens Res; 2020 Dec; 43(12):1459-1461. PubMed ID: 32733104
    [No Abstract]   [Full Text] [Related]  

  • 31. Cardiovascular actions of mixidine fumarate.
    Takeda K; Akera T; Brody TM
    Eur J Pharmacol; 1980 Nov; 68(2):129-37. PubMed ID: 7202482
    [No Abstract]   [Full Text] [Related]  

  • 32. Trial alert.
    Opie L
    Cardiovasc Drugs Ther; 1989 Dec; 3(6):795-6. PubMed ID: 2487542
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of adhesion molecules in cardiovascular pharmacology: meeting review.
    Virkhaus R; Lucchesi BR; Simpson PJ; Shebuski RJ
    J Pharmacol Exp Ther; 1995 May; 273(2):569-75. PubMed ID: 7752057
    [No Abstract]   [Full Text] [Related]  

  • 34. Cardiovascular effects of phosphodiesterase 5 inhibitors.
    Reffelmann T; Kloner RA
    Curr Pharm Des; 2006; 12(27):3485-94. PubMed ID: 17017941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The efficacy and safety of the drug treatment of cardiovascular diseases].
    Mazur NA
    Ter Arkh; 1993; 65(8):4-7. PubMed ID: 8211800
    [No Abstract]   [Full Text] [Related]  

  • 36. [Can endothelium be treated with drugs?].
    Fyhrquist F
    Duodecim; 1993; 109(20):1841-7. PubMed ID: 7737007
    [No Abstract]   [Full Text] [Related]  

  • 37. Cardiovascular pharmacology in the post-blockbuster era.
    Brandes RP
    Curr Opin Pharmacol; 2010 Apr; 10(2):109-10. PubMed ID: 20202904
    [No Abstract]   [Full Text] [Related]  

  • 38. Gp IIb/IIIa antagonists. Summary and table.
    Coleman SG; Duff R
    Drugs R D; 1999 May; 1(5):371-3. PubMed ID: 10566066
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of geranylgeranylacetone upon cardiovascular diseases.
    Zeng S; Wang H; Chen Z; Cao Q; Hu L; Wu Y
    Cardiovasc Ther; 2018 Aug; 36(4):e12331. PubMed ID: 29656548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Cardiovascular Therapeutics. Cambridge, MA, USA, June 10-11, 2003.
    Zavoico GB
    Cardiovasc Drug Rev; 2003; 21(3):246-53. PubMed ID: 14582482
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.